Zenas Biopharma Inc Forecast, price target & analysts
Zenas Biopharma Inc Target price 2026 - Analyst rating & recommendation
Zenas Biopharma Inc Classifications & Recommendation
Zenas Biopharma Inc Price Target
| Target Price | $45.90 |
| Price | $27.83 |
| Potential |
64.93%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Zenas Biopharma Inc 2027 .
The average Zenas Biopharma Inc target price is $45.90.
This is
64.93%
register free of charge
$61.95
122.60%
register free of charge
$32.32
16.13%
register free of charge
|
|
| A rating was issued by 14 analysts: 12 Analysts recommend Zenas Biopharma Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Zenas Biopharma Inc stock has an average upside potential 2027 of
64.93%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 10.00 | 1.02 |
| 100.00% | 89.80% | |
| EBITDA Margin | -2,113.30% | -32,648.15% |
| 35.47% | 1,444.89% | |
| Net Margin | -3,777.40% | -37,022.72% |
| 20.31% | 880.11% |
8 Analysts have issued a sales forecast Zenas Biopharma Inc 2026 . The average Zenas Biopharma Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Zenas Biopharma Inc EBITDA forecast 2026. The average Zenas Biopharma Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Zenas Biopharma Inc Analysts have issued a net profit forecast 2026. The average Zenas Biopharma Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -8.44 | -5.96 |
| 29.02% | 29.38% | |
| P/E | negative | |
| EV/Sales | 1,560.59 |
8 Analysts have issued a Zenas Biopharma Inc forecast for earnings per share. The average Zenas Biopharma Inc EPS is
This results in the following potential growth metrics and future valuations:
Zenas Biopharma Inc...
Current Zenas Biopharma Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citigroup |
Locked
➜
Locked
|
Locked | Sep 30 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 30 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Sep 30 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 15 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citigroup:
Locked
➜
Locked
|
Sep 30 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 30 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Sep 30 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 15 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
